151 related articles for article (PubMed ID: 10533461)
1. Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug.
Breistøl K; Hendriks HR; Fodstad O
Eur J Cancer; 1999 Jul; 35(7):1143-9. PubMed ID: 10533461
[TBL] [Abstract][Full Text] [Related]
2. The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.
Breistøl K; Hendriks HR; Berger DP; Langdon SP; Fiebig HH; Fodstad O
Eur J Cancer; 1998 Sep; 34(10):1602-6. PubMed ID: 9893636
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
Boven E; de Jong J; Kuiper CM; Bast A; van der Vijgh WJ
Eur J Cancer; 1996 Jul; 32A(8):1382-7. PubMed ID: 8869103
[TBL] [Abstract][Full Text] [Related]
4. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
5. Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.
de Jong J; Klein I; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 1992; 31(2):156-60. PubMed ID: 1451235
[TBL] [Abstract][Full Text] [Related]
6. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
7. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
8. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.
Boven E; Hendriks HR; Erkelens CA; Pinedo HM
Br J Cancer; 1992 Dec; 66(6):1044-7. PubMed ID: 1457343
[TBL] [Abstract][Full Text] [Related]
10. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
11. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
12. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
Devalapally H; Rajan KS; Akkinepally RR; Devarakonda RK
Drug Dev Ind Pharm; 2008 Aug; 34(8):789-95. PubMed ID: 18608462
[TBL] [Abstract][Full Text] [Related]
14. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice.
Shiah JG; Dvorák M; Kopecková P; Sun Y; Peterson CM; Kopecek J
Eur J Cancer; 2001 Jan; 37(1):131-9. PubMed ID: 11165140
[TBL] [Abstract][Full Text] [Related]
16. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
[TBL] [Abstract][Full Text] [Related]
17. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
18. [Detecting doxorubicin concentration in KBv200 and KB cell xenografts in nude mice by high-performance liquid chromatography].
Deng WJ; Zeng ZL; Liang YJ; Dai CL; Zhang JY; Fu LW
Ai Zheng; 2008 Apr; 27(4):364-8. PubMed ID: 18423121
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL
J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247
[TBL] [Abstract][Full Text] [Related]
20. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
